Navigation Links
Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
Date:6/12/2013

DUBLIN, June 12, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3c9pm9/research_report) has announced the addition of the "Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.

In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.

Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.

In 2012, the market size of China's hospital-use anti-PH drugs reached CNY 3.67 billion, increasing by 12.6% YOY.

Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China's hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.

In the coming years, a large group of branded drugs will successively lose patent protection, which is a great opportunity for non-patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China's anti-PH drug market is very bright. The annual growth rate of China's anti-PH drug market size is predicted to be over 10% in years to come.

More following information can be acquired through this report:

- Current R&D Status of Anti-PH Drugs
- Competition in China's Anti-PH Drug Market
- Market Sizes of China's Major Anti-PH Drugs
- Prediction on Development of China's Anti-PH Drugs

Following people are recommended to buy this report:

- Anti-PH Drug Manufacturers
- Pharmaceutical Agents/Hospitals
- Investors and Research Institutions Focusing on Anti-PH Drugs

Key Topics Covered:

1 Overview on Anti-Prostatic Hyperplasia (PH) Drugs
1.1 Definition of Prostatic Hyperplasia
1.2 Incidence

2 Overview on China's Anti-PH Drug Market, 2011-2012
2.1 Market Size
2.2 Market Shares of Major Drugs
2.3 Market Shares of Manufacturers

3 Analysis on Major Anti-PH Drugs in China's Market
3.1 5a-reductase Inhibitors
3.1.1 Finasteride
3.1.2 Epristeride
3.1.3 Dutasteride
3.2 a 1-adrenaline Receptor Antagonists
3.2.1 Tamsulosin
3.2.2 Doxazosin
3.2.3 Terazosin
3.2.4 Alfuzosin
3.3 Phytomedicine-Cernilton

4 Survey of Major Anti-PH Drug Prices in China's Market, 2011-2013

5 Prediction on Development of China's Anti-PH Drugs, 2013-2017
5.1 Prediction on Market Size
5.2 Prediction on Technological Trends

For more information visit http://www.researchandmarkets.com/research/3c9pm9/research_report
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... A study recently published in Spine shows ... center (ASC) with satisfactory clinical and patient-reported outcomes, when compared to anterior cervical ... Lubinski, president of AxioMed, commented on the recent publication, stating, “We see cervical ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
Breaking Biology Technology:
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/19/2017)... India , January 19, 2017 According to a ... Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is expected ... 2016 to 2022. In 2015, Asia-Pacific dominated the global ... and private sectors. Continue Reading ... ...
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
Breaking Biology News(10 mins):